[Efficacy and safety of tocilizumab in patients with Takayasu arteritis].
Identifieur interne : 000246 ( PubMed/Checkpoint ); précédent : 000245; suivant : 000247[Efficacy and safety of tocilizumab in patients with Takayasu arteritis].
Auteurs : H. Liao [République populaire de Chine] ; L L Pan ; J. Du ; N. Gao ; T. WangSource :
- Zhonghua nei ke za zhi [ 0578-1426 ] ; 2019.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux humanisés (administration et posologie), Anticorps monoclonaux humanisés (usage thérapeutique), Cyclophosphamide (administration et posologie), Cyclophosphamide (usage thérapeutique), Humains, Maladie de Takayashu (anatomopathologie), Maladie de Takayashu (traitement médicamenteux), Résultat thérapeutique, Études rétrospectives.
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Cyclophosphamide.
- anatomopathologie : Maladie de Takayashu.
- traitement médicamenteux : Maladie de Takayashu.
- usage thérapeutique : Anticorps monoclonaux humanisés, Cyclophosphamide.
- Humains, Résultat thérapeutique, Études rétrospectives.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (therapeutic use), Cyclophosphamide (administration & dosage), Cyclophosphamide (therapeutic use), Humans, Retrospective Studies, Takayasu Arteritis (drug therapy), Takayasu Arteritis (pathology), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Cyclophosphamide.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Cyclophosphamide.
- drug therapy : Takayasu Arteritis.
- pathology : Takayasu Arteritis.
- Humans, Retrospective Studies, Treatment Outcome.
Abstract
Objective: To assess the efficacy and safety of tocilizumab and cyclophosphamide in patients with Takayasu arteritis (TA). Methods: Twenty-seven TA patients treated with tocilizumab (TCZ group) and 22 treated with cyclophosphamide (CTX group) were enrolled and retrospectively analyzed. The duration of treatment was 6 months. Disease activity and side effects were compared between the two groups. Results: After treatment, the median C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and disease activity scores in TCZ group were significantly lower than those in CTX group respectively [ESR 3 mm/1h vs. 8 mm/1h; CRP 0.13 mg/L vs. 1.09 mg/L; National Institutes of Health (NIH) score 0(0,1) vs. 0(1,1); the Indian Takayasu clinical activity score (ITAS 2010) 0(0,2) vs. 2(0,3.5), and the Indian Takayasu activity score with the acute phase response (ITAS-A) 0(0,2) vs. 2.5(0,3.5); all P<0.05]. The daily prednisone doses before treatment and after treatment in TCZ group were significantly lower than those in CTX group [(20.1±15.9) mg/d vs. (39.3±16.7) mg/d;(5.1±4.2)mg/d vs. (12.1±4.6) mg/d,both P<0.05)].The incidence of drug-related side effects in TCZ group was significantly lower than that in CTX group, which was 22.2% vs. 54.5% (P<0.05). Conclusion: Compared with CTX treatment, TCZ treatment for TA with less prednisone has better efficacy and safety.
DOI: 10.3760/cma.j.issn.0578-1426.2019.06.009
PubMed: 31159524
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:31159524Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Efficacy and safety of tocilizumab in patients with Takayasu arteritis].</title><author><name sortKey="Liao, H" sort="Liao, H" uniqKey="Liao H" first="H" last="Liao">H. Liao</name><affiliation wicri:level="1"><nlm:affiliation>Departments of Rheumatology and Immunology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Departments of Rheumatology and Immunology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Pan, L L" sort="Pan, L L" uniqKey="Pan L" first="L L" last="Pan">L L Pan</name></author><author><name sortKey="Du, J" sort="Du, J" uniqKey="Du J" first="J" last="Du">J. Du</name></author><author><name sortKey="Gao, N" sort="Gao, N" uniqKey="Gao N" first="N" last="Gao">N. Gao</name></author><author><name sortKey="Wang, T" sort="Wang, T" uniqKey="Wang T" first="T" last="Wang">T. Wang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31159524</idno><idno type="pmid">31159524</idno><idno type="doi">10.3760/cma.j.issn.0578-1426.2019.06.009</idno><idno type="wicri:Area/PubMed/Corpus">000375</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000375</idno><idno type="wicri:Area/PubMed/Curation">000375</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000375</idno><idno type="wicri:Area/PubMed/Checkpoint">000246</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000246</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Efficacy and safety of tocilizumab in patients with Takayasu arteritis].</title><author><name sortKey="Liao, H" sort="Liao, H" uniqKey="Liao H" first="H" last="Liao">H. Liao</name><affiliation wicri:level="1"><nlm:affiliation>Departments of Rheumatology and Immunology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Departments of Rheumatology and Immunology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Pan, L L" sort="Pan, L L" uniqKey="Pan L" first="L L" last="Pan">L L Pan</name></author><author><name sortKey="Du, J" sort="Du, J" uniqKey="Du J" first="J" last="Du">J. Du</name></author><author><name sortKey="Gao, N" sort="Gao, N" uniqKey="Gao N" first="N" last="Gao">N. Gao</name></author><author><name sortKey="Wang, T" sort="Wang, T" uniqKey="Wang T" first="T" last="Wang">T. Wang</name></author></analytic><series><title level="j">Zhonghua nei ke za zhi</title><idno type="ISSN">0578-1426</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Cyclophosphamide (administration & dosage)</term><term>Cyclophosphamide (therapeutic use)</term><term>Humans</term><term>Retrospective Studies</term><term>Takayasu Arteritis (drug therapy)</term><term>Takayasu Arteritis (pathology)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Cyclophosphamide (administration et posologie)</term><term>Cyclophosphamide (usage thérapeutique)</term><term>Humains</term><term>Maladie de Takayashu (anatomopathologie)</term><term>Maladie de Takayashu (traitement médicamenteux)</term><term>Résultat thérapeutique</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Cyclophosphamide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Cyclophosphamide</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Cyclophosphamide</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Maladie de Takayashu</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Takayasu Arteritis</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Takayasu Arteritis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie de Takayashu</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Cyclophosphamide</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Retrospective Studies</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Résultat thérapeutique</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Objective:</b> To assess the efficacy and safety of tocilizumab and cyclophosphamide in patients with Takayasu arteritis (TA). <b>Methods:</b> Twenty-seven TA patients treated with tocilizumab (TCZ group) and 22 treated with cyclophosphamide (CTX group) were enrolled and retrospectively analyzed. The duration of treatment was 6 months. Disease activity and side effects were compared between the two groups. <b>Results:</b> After treatment, the median C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and disease activity scores in TCZ group were significantly lower than those in CTX group respectively [ESR 3 mm/1h vs. 8 mm/1h; CRP 0.13 mg/L vs. 1.09 mg/L; National Institutes of Health (NIH) score 0(0,1) vs. 0(1,1); the Indian Takayasu clinical activity score (ITAS 2010) 0(0,2) vs. 2(0,3.5), and the Indian Takayasu activity score with the acute phase response (ITAS-A) 0(0,2) vs. 2.5(0,3.5); all <i>P<</i>0.05]. The daily prednisone doses before treatment and after treatment in TCZ group were significantly lower than those in CTX group [(20.1±15.9) mg/d vs. (39.3±16.7) mg/d;(5.1±4.2)mg/d vs. (12.1±4.6) mg/d,both <i>P<</i>0.05)].The incidence of drug-related side effects in TCZ group was significantly lower than that in CTX group, which was 22.2% vs. 54.5% (<i>P<</i>0.05). <b>Conclusion:</b> Compared with CTX treatment, TCZ treatment for TA with less prednisone has better efficacy and safety.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31159524</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0578-1426</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Zhonghua nei ke za zhi</Title><ISOAbbreviation>Zhonghua Nei Ke Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Efficacy and safety of tocilizumab in patients with Takayasu arteritis].</ArticleTitle><Pagination><MedlinePgn>444-448</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.0578-1426.2019.06.009</ELocationID><Abstract><AbstractText><b>Objective:</b> To assess the efficacy and safety of tocilizumab and cyclophosphamide in patients with Takayasu arteritis (TA). <b>Methods:</b> Twenty-seven TA patients treated with tocilizumab (TCZ group) and 22 treated with cyclophosphamide (CTX group) were enrolled and retrospectively analyzed. The duration of treatment was 6 months. Disease activity and side effects were compared between the two groups. <b>Results:</b> After treatment, the median C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and disease activity scores in TCZ group were significantly lower than those in CTX group respectively [ESR 3 mm/1h vs. 8 mm/1h; CRP 0.13 mg/L vs. 1.09 mg/L; National Institutes of Health (NIH) score 0(0,1) vs. 0(1,1); the Indian Takayasu clinical activity score (ITAS 2010) 0(0,2) vs. 2(0,3.5), and the Indian Takayasu activity score with the acute phase response (ITAS-A) 0(0,2) vs. 2.5(0,3.5); all <i>P<</i>0.05]. The daily prednisone doses before treatment and after treatment in TCZ group were significantly lower than those in CTX group [(20.1±15.9) mg/d vs. (39.3±16.7) mg/d;(5.1±4.2)mg/d vs. (12.1±4.6) mg/d,both <i>P<</i>0.05)].The incidence of drug-related side effects in TCZ group was significantly lower than that in CTX group, which was 22.2% vs. 54.5% (<i>P<</i>0.05). <b>Conclusion:</b> Compared with CTX treatment, TCZ treatment for TA with less prednisone has better efficacy and safety.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Departments of Rheumatology and Immunology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>L L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>91739111</GrantID><Agency>National Natural Science Foundation of China</Agency><Country></Country></Grant><Grant><GrantID>15P07</GrantID><Agency>Capital Medical University Beijing Anzhen Hospital Dean of Science and Technology Development Fund</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nei Ke Za Zhi</MedlineTA><NlmUniqueID>16210490R</NlmUniqueID><ISSNLinking>0578-1426</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013625" MajorTopicYN="N">Takayasu Arteritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>目的：</b> 探讨托珠单抗治疗大动脉炎患者的有效性和安全性。 <b>方法：</b> 纳入2015年1月至2018年6月首都医科大学附属北京安贞医院风湿免疫科住院且未经治疗的大动脉炎患者，27例应用托珠单抗联合激素治疗（托珠单抗组），22例应用环磷酰胺联合激素治疗（环磷酰胺组），连续应用6个月，比较治疗前后美国国立卫生研究院大动脉炎评分（简称NIH评分）、印度北方医学科学研究所2010年印度大动脉炎活动度评分（简称ITAS2010评分）、印度北方医学科学研究所印度大动脉炎活动度-A评分（简称ITAS-A评分）、红细胞沉降率、C反应蛋白等及泼尼松用量和药物副作用。 <b>结果：</b> 托珠单抗组治疗后红细胞沉降率[3（2，6）mm/1h比8（5，17）mm/1h]、C反应蛋白[0.13（0.05，0.99）mg/L比1.09（0.46，3.33）mg/L]、NIH评分[0（0，1）比0（1，1）]、ITAS2010评分[0（0，2）比2（0，3.5）]、ITAS-A评分[0（0，2）比2.5（0，3.5）]较环磷酰胺组明显下降，差异均有统计学意义（<i>P</i>值均<0.05）。泼尼松用量托珠单抗组显著少于环磷酰胺组[治疗前：（20.1±15.9）mg/d比（39.3±16.7）mg/d，<i>P<</i>0.05；治疗后：（5.1±4.2）mg/d比（12.1±4.6）mg/d，<i>P<</i>0.05]。药物相关副作用发生率托珠单抗组（22.2%）低于环磷酰胺组（54.5%），差异有统计学意义（<i>P<</i>0.05）。 <b>结论：</b> 托珠单抗治疗大动脉炎有较好疗效，糖皮质激素用量及其副作用少于环磷酰胺。.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Interleukin-6</Keyword><Keyword MajorTopicYN="N">Takayasu</Keyword><Keyword MajorTopicYN="N">Tocilizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31159524</ArticleId><ArticleId IdType="doi">10.3760/cma.j.issn.0578-1426.2019.06.009</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country><settlement><li>Pékin</li></settlement></list><tree><noCountry><name sortKey="Du, J" sort="Du, J" uniqKey="Du J" first="J" last="Du">J. Du</name><name sortKey="Gao, N" sort="Gao, N" uniqKey="Gao N" first="N" last="Gao">N. Gao</name><name sortKey="Pan, L L" sort="Pan, L L" uniqKey="Pan L" first="L L" last="Pan">L L Pan</name><name sortKey="Wang, T" sort="Wang, T" uniqKey="Wang T" first="T" last="Wang">T. Wang</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Liao, H" sort="Liao, H" uniqKey="Liao H" first="H" last="Liao">H. Liao</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000246 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000246 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:31159524
|texte= [Efficacy and safety of tocilizumab in patients with Takayasu arteritis].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:31159524" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |